TY - JOUR
T1 - In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma
AU - Philipp-Abbrederis, Kathrin
AU - Herrmann, Ken
AU - Knop, Stefan
AU - Schottelius, Margret
AU - Eiber, Matthias
AU - Lückerath, Katharina
AU - Pietschmann, Elke
AU - Habringer, Stefan
AU - Gerngroß, Carlos
AU - Franke, Katharina
AU - Rudelius, Martina
AU - Schirbel, Andreas
AU - Lapa, Constantin
AU - Schwamborn, Kristina
AU - Steidle, Sabine
AU - Hartmann, Elena
AU - Rosenwald, Andreas
AU - Kropf, Saskia
AU - Beer, Ambros J.
AU - Peschel, Christian
AU - Einsele, Hermann
AU - Buck, Andreas K.
AU - Schwaiger, Markus
AU - Götze, Katharina
AU - Wester, Hans Jürgen
AU - Keller, Ulrich
N1 - Publisher Copyright:
© 2015 The Authors. Published under the terms of the CC BY 4.0 license.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination and poor prognosis. We evaluated the novel CXCR4 probe [68Ga]Pentixafor for in vivo mapping of CXCR4 expression density in mice xenografted with human CXCR4-positive MM cell lines and patients with advanced MM by means of positron emission tomography (PET). [68Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14 patients with advanced MM [68Ga]Pentixafor PET/CT scans revealed MM manifestations, whereas only nine of 14 standard [18F]fluorodeoxyglucose PET/CT scans were rated visually positive. Assessment of blood counts and standard CD34+ flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR4 expression in a cohort of MM patients, we conclude that [68Ga]Pentixafor PET opens a broad field for clinical investigations on CXCR4 expression and for CXCR4-directed therapeutic approaches in MM and other diseases.
AB - CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination and poor prognosis. We evaluated the novel CXCR4 probe [68Ga]Pentixafor for in vivo mapping of CXCR4 expression density in mice xenografted with human CXCR4-positive MM cell lines and patients with advanced MM by means of positron emission tomography (PET). [68Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14 patients with advanced MM [68Ga]Pentixafor PET/CT scans revealed MM manifestations, whereas only nine of 14 standard [18F]fluorodeoxyglucose PET/CT scans were rated visually positive. Assessment of blood counts and standard CD34+ flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR4 expression in a cohort of MM patients, we conclude that [68Ga]Pentixafor PET opens a broad field for clinical investigations on CXCR4 expression and for CXCR4-directed therapeutic approaches in MM and other diseases.
KW - CXCR4
KW - Chemokine receptor
KW - Multiple myeloma
KW - Positron emission tomography
KW - in vivo imaging
UR - https://www.scopus.com/pages/publications/84926200332
U2 - 10.15252/emmm.201404698
DO - 10.15252/emmm.201404698
M3 - Article
C2 - 25736399
AN - SCOPUS:84926200332
SN - 1757-4676
VL - 7
SP - 477
EP - 487
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
IS - 4
ER -